← All trials
NCT05664061
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 20, 2022
- Primary completion
- Jul 31, 2023
- Completion date
- Dec 31, 2023
- First posted
- Dec 23, 2022
- Last posted
- Dec 23, 2022
- Enrollment
- 451
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Respirent Pharmaceuticals Co Ltd.Lead sponsor
- University of IoanninaOverall official - principal investigator
- BECRO Ltd.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.